The FINANCIAL — AstraZeneca on October 23 announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of ...

In clinical trials, treatment with Bydureon BCise resulted in average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds when used as monotherapy or as an add-on to metormin, a ...

BYDUREON BCISE The expanded approval was based on data from a phase 3 study that evaluated exenatide extended-release in 82 patients aged 10 to 17 years with type 2 diabetes. The Food and Drug ...

Bydrueon BCise is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. AstraZeneca announced the launch of Bydureon BCise (exenatide ...

Against the backdrop of challenges for its Type 2 diabetes Bydureon business, AstraZeneca has received some good news from the FDA. The U.S. regulatory agency green lit the therapy in children, making ...

WILMINGTON, Del., Jan. 10, 2018 /PRNewswire/ -- AstraZeneca today announced that BYDUREON ® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the ...

(Sharecast News) - AstraZeneca announced on Thursday that the European Commission (EC) has approved Bydureon BCise - exenatide 2mg prolonged-release suspension for injection in pre-filled pen - as a ...

European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes The new formulation of once-weekly Bydureon is an improved single-dose, pre-filled pen ...

BYDUREON BCise (exenatide extended-release) is the first once-weekly GLP-1 RA treatment option for pediatric patients with type 2 diabetes in the US AstraZeneca’s BYDUREON BCise ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved the GLP-1 receptor agonist exenatide ...

Unlike other glucagon-like peptide-1 (GLP-1) receptor agonists, BYDUREON BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the ...

* Astrazeneca PLC - ‍BYDUREON BCise will be available for patients in US in Q1 of 2018 Source text for Eikon: Further company coverage: Sign up here. Autos & Transportationcategory EU executive to ...